Latest Articles
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial - Medpage Today
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial Medpage Today
Published: Feb. 5, 2025, 5:54 p.m.
FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer - OncLive
FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer OncLive
Published: Feb. 5, 2025, 5:17 p.m.
Serac Healthcare Announces Successful FDA End of Phase II Meeting for Endometriosis Imaging Agent - Imaging Technology News
Serac Healthcare Announces Successful FDA End of Phase II Meeting for Endometriosis Imaging Agent Imaging Technology News
Published: Feb. 5, 2025, 3:56 p.m.
Endometriosis explained as Steve Irwin's daughter recalls 10 years of 'agonising pain' before diagnosis - Daily Record
Endometriosis explained as Steve Irwin's daughter recalls 10 years of 'agonising pain' before diagnosis Daily Record
Published: Feb. 5, 2025, 3:33 p.m.
Married to Medicine’s Lateasha Lunceford Shares Update on Growing Her Family With Dr. Greg - Reality Tea
Married to Medicine’s Lateasha Lunceford Shares Update on Growing Her Family With Dr. Greg Reality Tea
Published: Feb. 5, 2025, 3:18 p.m.
Serac Healthcare Announces Successful FDA End of Phase II Meeting for Endometriosis Imaging Agent - StreetInsider.com
Serac Healthcare Announces Successful FDA End of Phase II Meeting for Endometriosis Imaging Agent StreetInsider.com
Published: Feb. 5, 2025, 1:51 p.m.
Serac Healthcare Announces Successful FDA End of Phase II Meeting for Endometriosis Imaging Agent - Yahoo Finance
Serac Healthcare Announces Successful FDA End of Phase II Meeting for Endometriosis Imaging Agent Yahoo Finance
Published: Feb. 5, 2025, 1:51 p.m.
A Case of Postoperative Lymphatic Ascites in Endometrial Cancer Spontaneously Resolving After Approximately One Year of Watchful Waiting - Cureus
A Case of Postoperative Lymphatic Ascites in Endometrial Cancer Spontaneously Resolving After Approximately One Year of Watchful Waiting Cureus
Published: Feb. 5, 2025, 1:26 p.m.
Acrivon Therapeutics Announces FDA has Granted Breakthrough - GlobeNewswire
Acrivon Therapeutics Announces FDA has Granted Breakthrough GlobeNewswire
Published: Feb. 5, 2025, 1:19 p.m.
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer The Manila Times
Published: Feb. 5, 2025, 1:07 p.m.
Link copied to clipboard!